T cell exhaustion remains a critical barrier in treating chronic infections and cancer. To overcome this, our laboratory has established a platform for generating "rejuvenated" T cells from induced pluripotent stem cells (iPSCs). This review outlines our research trajectory, transitioning from the foundational autologous "T-iPSC" concept to scalable, "off-the-shelf" allogeneic strategies. We detail the establishment of clinical-grade, xeno-free manufacturing protocols and the integration of advanced gene editing-including functional enhancement through intracellular signaling modulation, immune rejection-related gene editing to minimize immunogenicity, and optimization of synthetic receptor architectures to mitigate the risk of Graft-versus-Host Disease (GvHD) while enhancing targeting efficiency. Furthermore, we describe our activity on generating regulatory T cells from iPSC for managing autoimmune disorders and GvHD. Finally, we discuss the remaining challenges and the future roadmap for translating these therapeutic T cells into clinical practice.
Wang et al. (Sat,) studied this question.